EP1151295A4 - Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products - Google Patents

Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products

Info

Publication number
EP1151295A4
EP1151295A4 EP00907081A EP00907081A EP1151295A4 EP 1151295 A4 EP1151295 A4 EP 1151295A4 EP 00907081 A EP00907081 A EP 00907081A EP 00907081 A EP00907081 A EP 00907081A EP 1151295 A4 EP1151295 A4 EP 1151295A4
Authority
EP
European Patent Office
Prior art keywords
methods
therapeutically effective
cultured cells
cell membranes
antineoplastic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00907081A
Other languages
German (de)
French (fr)
Other versions
EP1151295A1 (en
Inventor
Eckard Weber
Ben Y Tseng
John Drewe
Sui Xiong Cai
Shailaja Kasibhatla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytovia Therapeutics LLC
Original Assignee
Cytovia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytovia Inc filed Critical Cytovia Inc
Publication of EP1151295A1 publication Critical patent/EP1151295A1/en
Publication of EP1151295A4 publication Critical patent/EP1151295A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00907081A 1999-02-01 2000-02-01 Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products Withdrawn EP1151295A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11810299P 1999-02-01 1999-02-01
US118102P 1999-02-01
US45459599A 1999-12-07 1999-12-07
US454595 1999-12-07
PCT/US2000/002329 WO2000045165A1 (en) 1999-02-01 2000-02-01 Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products

Publications (2)

Publication Number Publication Date
EP1151295A1 EP1151295A1 (en) 2001-11-07
EP1151295A4 true EP1151295A4 (en) 2005-03-30

Family

ID=26815975

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00907081A Withdrawn EP1151295A4 (en) 1999-02-01 2000-02-01 Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products

Country Status (3)

Country Link
EP (1) EP1151295A4 (en)
AU (1) AU2864100A (en)
WO (1) WO2000045165A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342611B1 (en) 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
US6248904B1 (en) 1998-07-21 2001-06-19 Cytovia, Inc. Fluorescence dyes and their applications for whole-cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
AU2001278135A1 (en) 2000-08-03 2002-02-18 Cytovia, Inc. Method of identifying immunosuppressive agents
KR100545930B1 (en) * 2001-05-11 2006-01-25 우석대학교 산학협력단 Pharmaceutical compositions comprising cellidonin or derivatives thereof
DE10206849A1 (en) * 2002-02-18 2005-07-28 Aventis Pharma Deutschland Gmbh Phenalenone derivatives, process for making and using same
US7253206B2 (en) 2002-02-18 2007-08-07 Sanofi-Aventis Deutschland Gmbh Phenalenone derivatives, processes for preparation and use thereof
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
WO2004002428A2 (en) * 2002-07-01 2004-01-08 Cytovia, Inc. Derivatives of gambogic acid and induce apoptosis
WO2004032876A2 (en) * 2002-10-11 2004-04-22 Board Of Regents, The University Of Texas System Deguelin as a chemopreventive agent for lung cancer
ATE509630T1 (en) * 2004-09-02 2011-06-15 Bionaut Pharmaceuticals Inc PANCREAS CANCER TREATMENT WITH NA+/K+-ATPASE INHIBITORS
EP1789090A2 (en) * 2004-09-02 2007-05-30 Bionaut Pharmaceuticals, Inc. Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors
EP1655027A1 (en) * 2004-11-04 2006-05-10 Biofrontera Pharmaceuticals GmbH 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension and migraine
JP2009274956A (en) * 2006-08-28 2009-11-26 Univ Nihon Malignant tumor-treating agent originated from neem seed
WO2008058269A2 (en) * 2006-11-09 2008-05-15 Foldrx Pharmaceuticals, Inc. Compounds and methods for modulating protein trafficking
JP2008222603A (en) * 2007-03-09 2008-09-25 Institute Of Physical & Chemical Research Preventive and therapeutic agent of neurodegenerative disease
EP2420239B1 (en) * 2007-04-13 2015-01-14 Southern Research Institute Clomipramine as anti-angiogenic agent
US20120128684A1 (en) * 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
CN101869574B (en) * 2010-07-24 2011-12-21 南京大学 Application of uabain for enhancing cellular sensitivity of non-small cell lung cancer (NSCLC)
CN103764659A (en) * 2011-06-15 2014-04-30 生命与大脑有限公司 Glioblastoma inhibiting compounds and their use
CN102675273A (en) * 2012-05-03 2012-09-19 吉林大学 3-aryl-8-allyl-7-hydroxy (methoxyl) coumarin and application in preparation of antitumor drugs
SG11201710272VA (en) * 2015-06-19 2018-01-30 Etsuko Miyamoto Protein degradation inducing tag and usage thereof
AU2015101721A4 (en) * 2015-11-26 2016-01-07 Macau University Of Science And Technology Prenylated isoflavones for treatment of subjects with multidrug-resistant cancer
CN107602445B (en) * 2016-07-12 2020-12-01 中国科学院上海药物研究所 Loperamide derivative and application thereof in preparation of medicine for treating mixed lineage leukemia
KR102600091B1 (en) * 2016-08-24 2023-11-09 (주)아모레퍼시픽 Composition for skin-whitening comprising cytochalasin d
MX2019005600A (en) 2016-11-15 2019-10-09 Univ Tokyo Science Found Ras PROTEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION.
WO2018092725A1 (en) 2016-11-15 2018-05-24 学校法人東京理科大学 p53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
CN108096246B (en) * 2017-03-08 2020-07-14 中国农业科学院饲料研究所 Application of quercetin and aconitine in preparation of medicine for treating cervical cancer and medicine for treating cervical cancer
CN107219201B (en) * 2017-04-20 2019-11-12 浙江工商大学 Utilize the immune rear bullfrog antibody of fluorescence microscope citrinin and affine method
CN112516134B (en) * 2019-09-18 2023-06-06 上海医药集团股份有限公司 Application of hydroxyl-containing compound in preparation of medicines
WO2021067799A1 (en) * 2019-10-02 2021-04-08 The General Hospital Corporation Methods and materials for modulating nrf2 pathway
US20240139162A1 (en) * 2019-10-17 2024-05-02 Chengdu Anticancer Bioscience, Ltd. Benzophenanthridine Alkaloids and Their Methods of Use
CN111317734A (en) * 2020-03-27 2020-06-23 广州医科大学附属第二医院 Wnt signal pathway inhibitor and application
CN112545979B (en) * 2021-01-12 2022-07-19 山西省肿瘤研究所 Perfusion gel for preventing postoperative recurrence of bladder cancer and preparation method and application thereof
CN113559110A (en) * 2021-08-27 2021-10-29 上海市第一人民医院 Application of ouabain in preparation of Nrf2 inhibitor and medicine for treating diseases related to abnormal activation of Nrf2

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821072A (en) * 1996-02-20 1998-10-13 Sloan-Kettering Institute For Cancer Research Combinations of PKC inhibitors and therapaeutic agents for treating cancers
WO1998053091A1 (en) * 1997-05-22 1998-11-26 The Burnham Institute Screening assays for agents that alter inhibitor of apoptosis (iap) protein regulation of caspase activity
WO1998055863A1 (en) * 1997-06-05 1998-12-10 Idun Pharmaceuticals, Inc. Rapid methods for identifying modifiers of cellular apoptosis activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821072A (en) * 1996-02-20 1998-10-13 Sloan-Kettering Institute For Cancer Research Combinations of PKC inhibitors and therapaeutic agents for treating cancers
WO1998053091A1 (en) * 1997-05-22 1998-11-26 The Burnham Institute Screening assays for agents that alter inhibitor of apoptosis (iap) protein regulation of caspase activity
WO1998055863A1 (en) * 1997-06-05 1998-12-10 Idun Pharmaceuticals, Inc. Rapid methods for identifying modifiers of cellular apoptosis activity

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FULDA ET AL: "Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 21, 1 November 1997 (1997-11-01), pages 4956 - 4964, XP002128611, ISSN: 0008-5472 *
GAMEN S ET AL: "Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 417, no. 3, 17 November 1997 (1997-11-17), pages 360 - 364, XP004261485, ISSN: 0014-5793 *
KAWAHARA ATSUO ET AL: "Fas-induced DNA fragmentation and proteolysis of nuclear proteins", GENES TO CELLS, vol. 3, no. 5, May 1998 (1998-05-01), pages 297 - 306, XP002298457, ISSN: 1356-9597 *
LOS M ET AL: "REQUIREMENT OF AN ICE/CED-3 PROTEASE FOR FAS/APO-1-MEDIATED APOPTOSIS", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 375, no. 6526, 4 May 1995 (1995-05-04), pages 81 - 83, XP000574811, ISSN: 0028-0836 *
SCHWARTZ S M: "Cell death and the caspase cascade.", CIRCULATION. 27 JAN 1998, vol. 97, no. 3, 27 January 1998 (1998-01-27), pages 227 - 229, XP002298456, ISSN: 0009-7322 *
See also references of WO0045165A1 *
VILLA P ET AL: "Caspases and caspase inhibitors", TIBS TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER PUBLICATION, CAMBRIDGE, EN, vol. 22, no. 10, 1 October 1997 (1997-10-01), pages 388 - 393, XP004091999, ISSN: 0968-0004 *

Also Published As

Publication number Publication date
AU2864100A (en) 2000-08-18
EP1151295A1 (en) 2001-11-07
WO2000045165A1 (en) 2000-08-03

Similar Documents

Publication Publication Date Title
EP1151295A4 (en) Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products
AU4965799A (en) Bioreactor and cell culturing processes using the bioreactor
IL144359A0 (en) Immortalized cell lines and methods of making the same
AU3914300A (en) Cell culture apparatus and method for culturing cells
AU2001254885A1 (en) Modified ES cells and ES cell-specific gene
AU1644295A (en) Cell culture substrates and methods of use
DE69617583D1 (en) In vitro cell culture system
AU1674697A (en) Vectors and methods for providing cells with additional nucleic acid material integrated in the genome of said cells
AU2295201A (en) Spore-like cells and uses thereof
AU7372900A (en) Electrochemical cell having beaded can and method of forming same
GB9605453D0 (en) Cultured cells
GB9516556D0 (en) Cell culture laminate
EP1221853A4 (en) Oligodendrocyte cell cultures and methods for their preparation and use
GB2314332B (en) Gene expression in mammalian cells
EP1072682A4 (en) Protein and gene participating in the differentiation of immortalized cells
WO2001013446A2 (en) Material for positive electrode of lithium secondary cell and method for preparing the same
GB9705744D0 (en) Methods for selecting cells and their uses
AU7625600A (en) Electrochemical cell and cell assembly process
AU9276398A (en) Materials and methods relating to the stimulation of cells
EP1051915A4 (en) Fermented organic acid that changes cell and protein functions
AU5698500A (en) Assay method to identify s-phase cells on cell sections or permeabilised cells and uses thereof
AU4543196A (en) Transfert of dna in cells with the view to correcting the adrenoleucodystrophy
AU1335699A (en) Modified microcarriers and their use in cell cryoconservation
AU4760900A (en) Methods and gene products for altering the shape of cells and organs in plants
GB9709407D0 (en) Cell culture methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010823

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010823;LT PAYMENT 20010823;LV PAYMENT 20010823;MK PAYMENT 20010823;RO PAYMENT 20010823;SI PAYMENT 20010823

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KASIBHATLA, SHAILAJA

Inventor name: DREWE, JOHN

Inventor name: TSENG, BEN, Y.

Inventor name: WEBER, ECKARD

Inventor name: CAI, SUI, XIONG

RIC1 Information provided on ipc code assigned before grant

Ipc: 7G 01N 33/50 A

A4 Supplementary search report drawn up and despatched

Effective date: 20050211

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060620